KBLB logo

Kraig Biocraft Laboratories, Inc. (KBLB) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

$'dan işlem gören Kraig Biocraft Laboratories, Inc. (KBLB), 0 değerindeki bir Basic Materials şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 44/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
44/100 AI Puanı

Kraig Biocraft Laboratories, Inc. (KBLB) Malzemeler ve Emtia Maruziyeti

CEOKim Kraig Thompson
Çalışanlar37
MerkezAnn Arbor, US
Halka Arz Yılı2008

Kraig Biocraft Laboratories, Inc. specializes in developing and commercializing protein-based fibers, leveraging recombinant DNA technology for applications in technical textiles and specialty fibers. Targeting diverse sectors including defense, industrial, and medical, the company aims to disrupt traditional material science with innovative, high-performance solutions.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Kraig Biocraft Laboratories presents a high-risk, high-reward investment opportunity centered on its proprietary spider silk technology. The company's potential lies in disrupting the technical textile and specialty fiber markets with a sustainable, high-performance alternative to traditional materials. Key value drivers include successful scaling of spider silk production, securing significant contracts in target markets such as defense and aerospace, and achieving profitability. However, the company's negative profit margin of -13698.5% and negative gross margin of -15.1% highlight significant financial challenges. Upcoming catalysts include potential advancements in production efficiency and new partnerships. Investors should closely monitor the company's ability to secure funding and achieve commercial viability.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.13 billion indicates a small-cap company with potential for growth but also higher volatility.
  • P/E ratio of -35.29 reflects the company's current lack of profitability, suggesting it is an early-stage growth company.
  • Profit Margin of -13698.5% highlights significant operational inefficiencies and challenges in achieving profitability.
  • Gross Margin of -15.1% indicates that the company's cost of goods sold exceeds its revenue, requiring substantial improvements in production efficiency.
  • Beta of 1.33 suggests the stock is more volatile than the market, indicating higher risk and potential for larger price swings.

Rakipler & Benzerleri

Güçlü Yönler

  • Proprietary spider silk technology.
  • Potential for high-performance materials.
  • Sustainable and eco-friendly production process.
  • Diverse range of potential applications.

Zayıflıklar

  • Negative profit margin and gross margin.
  • Limited commercial production capacity.
  • Reliance on successful scaling of production.
  • Competition from established material companies.

Katalizörler

  • Upcoming: Potential advancements in spider silk production efficiency.
  • Upcoming: Securing new contracts in the defense or aerospace sectors.
  • Ongoing: Research and development efforts to expand applications of spider silk.
  • Ongoing: Partnerships with industry leaders to commercialize spider silk products.
  • Ongoing: Efforts to improve financial performance and achieve profitability.

Riskler

  • Ongoing: Negative profit margin and gross margin indicate financial instability.
  • Potential: Competition from established material companies.
  • Potential: Technological advancements by competitors.
  • Potential: Regulatory hurdles and compliance requirements.
  • Ongoing: Reliance on successful scaling of spider silk production.

Büyüme Fırsatları

  • Growth opportunity 1: Expansion into the defense and military textiles market represents a significant growth opportunity for Kraig Biocraft. Spider silk's exceptional strength and ballistic protection capabilities make it an ideal material for body armor and other protective gear. Securing contracts with defense agencies could drive substantial revenue growth. The global military textiles market is projected to reach billions of dollars, offering a large addressable market for Kraig Biocraft. Timeline: Ongoing.
  • Growth opportunity 2: Penetration of the aerospace composite materials market offers another avenue for growth. Spider silk can be used to reinforce composite materials, enhancing their strength and durability while reducing weight. This is particularly valuable in the aerospace industry, where weight reduction translates to fuel efficiency and improved performance. The aerospace composite materials market is expected to grow, driven by increasing demand for lightweight and fuel-efficient aircraft. Timeline: Ongoing.
  • Growth opportunity 3: Development of medical textile applications for spider silk presents a high-value growth opportunity. Spider silk's biocompatibility and strength make it suitable for sutures, wound dressings, and tissue scaffolds. The medical textiles market is growing, driven by advancements in healthcare technology and increasing demand for biocompatible materials. Kraig Biocraft can partner with medical device companies to develop and commercialize spider silk-based medical products. Timeline: Ongoing.
  • Growth opportunity 4: Licensing of Kraig Biocraft's spider silk technology to other companies in the textile and materials industries could generate significant revenue streams. Licensing agreements would allow other companies to utilize Kraig Biocraft's technology to develop and commercialize their own spider silk-based products. This strategy would expand the reach of Kraig Biocraft's technology and generate recurring revenue. Timeline: Ongoing.
  • Growth opportunity 5: Improving production efficiency and scaling up spider silk production is crucial for achieving profitability and meeting market demand. Investing in research and development to optimize silkworm breeding and silk extraction processes can significantly reduce production costs and increase output. This will enable Kraig Biocraft to compete more effectively with traditional materials and capture a larger share of the market. Timeline: Ongoing.

Fırsatlar

  • Expansion into defense, aerospace, and medical markets.
  • Licensing of spider silk technology.
  • Partnerships with industry leaders.
  • Increasing demand for sustainable materials.

Tehditler

  • Competition from alternative materials.
  • Technological advancements by competitors.
  • Regulatory hurdles and compliance requirements.
  • Economic downturn affecting demand for specialty materials.

Rekabet Avantajları

  • Proprietary recombinant DNA technology for spider silk production.
  • Patents protecting its spider silk technology.
  • First-mover advantage in the spider silk market.
  • Potential for strong brand recognition as a leader in advanced materials.

KBLB Hakkında

Kraig Biocraft Laboratories, Inc., founded in 2006 and headquartered in Ann Arbor, Michigan, is a biotechnology company focused on the development and commercialization of protein-based fibers. The company utilizes recombinant DNA technology to create advanced materials with unique properties, targeting the technical textile and specialty fiber industries. Kraig Biocraft's core innovation lies in genetically engineering silkworms to produce spider silk, a material known for its exceptional strength, elasticity, and toughness. These spider silk-based fibers are designed for a wide range of applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company's products also cater to niche markets such as medical textiles, geotextiles, defense and military textiles, protective clothing, filtration textiles, and functional textiles for buildings and transportation. Kraig Biocraft aims to replace traditional materials with sustainable, high-performance alternatives, positioning itself as a key player in the advanced materials sector.

Ne Yaparlar

  • Develops protein-based fibers using recombinant DNA technology.
  • Engineers silkworms to produce spider silk.
  • Creates advanced materials with unique properties.
  • Targets the technical textile and specialty fiber industries.
  • Offers spider silk-based fibers for ballistic protection.
  • Provides materials for industrial cables and safety equipment.
  • Develops composite materials for the aerospace industry.

İş Modeli

  • Develops and patents recombinant DNA technology for spider silk production.
  • Produces spider silk fibers through genetically engineered silkworms.
  • Sells spider silk fibers to manufacturers in various industries.
  • Potentially licenses its technology to other companies for revenue.

Sektör Bağlamı

Kraig Biocraft Laboratories operates within the specialty chemicals industry, a sector characterized by innovation in material science and increasing demand for high-performance and sustainable materials. The technical textile market, a key target for Kraig Biocraft, is projected to grow, driven by advancements in material technology and increasing applications in defense, aerospace, and healthcare. Competition includes established chemical companies and emerging biotech firms focused on advanced materials. Kraig Biocraft aims to differentiate itself through its proprietary spider silk technology, offering a unique combination of strength, elasticity, and sustainability.

Kilit Müşteriler

  • Manufacturers of ballistic protection equipment.
  • Companies producing industrial cables and safety equipment.
  • Aerospace companies using composite materials.
  • Medical device companies requiring biocompatible materials.
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Kraig Biocraft Laboratories, Inc. (KBLB) hisse senedi fiyatı: Price data unavailable

Son Haberler

KBLB için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

KBLB için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

KBLB için Wall Street fiyat hedefi analizi.

MoonshotScore

44/100

Bu puan ne anlama geliyor?

MoonshotScore, KBLB'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Kim Kraig Thompson

CEO

Kim Kraig Thompson serves as the CEO of Kraig Biocraft Laboratories, Inc. His background includes experience in business management and strategic development. He has been instrumental in guiding the company's focus on recombinant DNA technology and the commercialization of spider silk. Thompson's leadership is centered on driving innovation and expanding the applications of the company's unique materials.

Sicil: Under Kim Kraig Thompson's leadership, Kraig Biocraft Laboratories has focused on developing and patenting its spider silk technology. Key milestones include securing patents for its recombinant DNA processes and establishing partnerships to explore commercial applications. Thompson has overseen the company's efforts to scale up production and target key markets such as defense and aerospace.

KBLB OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Kraig Biocraft Laboratories may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles and speculative ventures.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity on the OTC market can be highly variable. Given that the stock trades on the OTC Other tier, it's likely to have lower trading volumes and wider bid-ask spreads compared to stocks on major exchanges. This can make it more difficult to buy or sell shares quickly and efficiently, potentially leading to price volatility and increased transaction costs.
OTC Risk Faktörleri:
  • Limited financial disclosure increases information asymmetry.
  • Lower liquidity can lead to price volatility.
  • Higher risk of fraud or manipulation compared to listed exchanges.
  • OTC Other tier status indicates potential financial or operational challenges.
  • Regulatory oversight is less stringent than on major exchanges.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's intellectual property and patents.
  • Check for any legal or regulatory issues.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor.
Meşruiyet Sinyalleri:
  • Patents protecting its spider silk technology.
  • Focus on developing high-performance materials.
  • Targeting diverse markets including defense and aerospace.
  • CEO with relevant experience in business management.
  • Company has been in operation since 2006.

Yatırımcılar Kraig Biocraft Laboratories, Inc. (KBLB) Hakkında Ne Soruyor

KBLB için değerlendirilmesi gereken temel faktörler nelerdir?

Kraig Biocraft Laboratories, Inc. (KBLB) şu anda yapay zeka skoru 44/100, düşük puanı gösteriyor. Temel güçlü yan: Proprietary spider silk technology.. İzlenmesi gereken birincil risk: Ongoing: Negative profit margin and gross margin indicate financial instability.. Bu bir finansal tavsiye değildir.

KBLB MoonshotScore'u nedir?

KBLB şu anda MoonshotScore'da 44/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

KBLB verileri ne sıklıkla güncellenir?

KBLB fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler KBLB hakkında ne diyor?

KBLB için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

KBLB'a yatırım yapmanın riskleri nelerdir?

KBLB için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Negative profit margin and gross margin indicate financial instability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

KBLB'ın P/E oranı nedir?

KBLB için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için KBLB'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

KBLB aşırı değerli mi, yoksa düşük değerli mi?

Kraig Biocraft Laboratories, Inc. (KBLB)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

KBLB'ın temettü verimi nedir?

Kraig Biocraft Laboratories, Inc. (KBLB) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on the most recent available information.
  • OTC market data may be limited or less reliable than data from major exchanges.
Veri Kaynakları

Popüler Hisseler